Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor  evolocumab: a prespecified secondary analysis of the FOURIER trial

LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much

one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between

progressively lower LDL-cholesterol concentrations achieved at 4 weeks and clinical efficacy and safety in the

FOURIER trial of evolocumab, a monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9).

DESCARGA ARTÍCULO COMPLETO

Publicaciones Similares

AACE/ACE Consensus Statement

PorSadeno

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2017 EXECUTIVE SUMMARY   Autores: Alan J. Garber, MD, PhD, FACE1; Martin J. Abrahamson, MD2; Joshua I. Barzilay, MD, FACE3; Lawrence Blonde, MD, FACP, FACE4; Zachary T. Bloomgarden, MD, MACE5; Michael A. Bush, MD6; Samuel…

Evolocumab and Clinical Outcomes in Patients with Card. Disease

PorSadeno

Descargue el artículo completo ABSTRACT BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels…

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial

PorSadeno

Consulta aquí el artículo: Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial

Actualización del algoritmo de hiperglucemia 2017

PorSadeno

La diabetes mellitus tipo 2 (DM2), por su elevada prevalencia, número de discapacidades y alto coste económico, constituye una de las enfermedades crónicas con mayor impacto para el individuo, los sistemas sanitarios y la sociedad. El abordaje multifactorial y el manejo de la hiperglucemia corresponden, fundamentalmente, al ámbito de la atención primaria. Sara Artola Menéndez Médico de familia. Centro de Salud…